Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 4 hours ago
FDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbuster
about 4 hours ago
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa...
BioCryst ends internal discovery programs, closes Alabama facility in pivot to cost-saving partnerships
about 4 hours ago
After scrapping development on its diabetic macular edema treatment avoralstat last month...
Evommune’s phase 2b trial flops, ending challenge to Novartis in hives
about 5 hours ago
A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint...
United Therapeutics nabs FDA approval for donor-lung assessment device
about 5 hours ago
United Therapeutics has been given a premarket approval from the FDA for...
Roche launches Axelios 1, its eagerly awaited gene sequencing rival to Illumina
about 6 hours ago
Roche may have failed to buy out Illumina back in 2012, but...
Production problems hamper Lantheus bid for FDA approval of radiopharma dx kit
about 6 hours ago
The FDA dealt Lantheus’ bid to garner approval of its radiodiopharmaceutical diagnostic...
UK-based Scancell bids to buy Nasdaq-listed Neuphoria to ‘increase profile’ with US investors
about 6 hours ago
As Neuphoria continues to navigate the fallout of its failed social anxiety...
Cash-strapped Alopexx reignites plans to go public via $30M IPO to fund infectious disease programs
about 6 hours ago
Alopexx has resuscitated its plans for a public listing as the biotech...
Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis
about 7 hours ago
Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for...
'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset
about 8 hours ago
Amid a flurry of traditional IPOs this spring, Talawar Therapeutics is taking...
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor
about 9 hours ago
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease...
Cardiac medtech HeartBeam drops CEO in restructuring aimed at global ECG platform push
3 days ago
HeartBeam, the maker of a cable-free ECG system, moved CEO Robert Eno...